MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance. The gene discussed is MEN1; the disease is pancreatic neuroendocrine tumor.